Sézary syndrome, recent biomarkers and new drugs

Cristina Cristofoletti, Maria Grazia Narducci, Giandomenico Russo

Research output: Contribution to journalReview articlepeer-review


Sézary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. In this context, we discuss the major malignancy-related biomarkers reported in the literature for the diagnosis, prognosis and staging of SS. The hope for a single reliable diagnostic marker appears increasingly unrealistic, but the discovery of multiple potential biomarkers, with pathogenetic implications, paves the road to promising personalized therapies in SS.

Original languageEnglish
Article number2
JournalChinese Clinical Oncology
Issue number1
Publication statusPublished - Feb 2019


  • Biomarkers
  • Clinical trials
  • Cutaneous T-cell lymphoma (CTCL)
  • Sézary syndrome (SS)
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Sézary syndrome, recent biomarkers and new drugs'. Together they form a unique fingerprint.

Cite this